vs
亚朵集团（ATAT）与Revvity（RVTY）财务数据对比。点击上方公司名可切换其他公司
亚朵集团的季度营收约是Revvity的1.0倍（$789.6M vs $772.1M），亚朵集团净利率更高（17.6% vs 12.7%，领先4.9%），亚朵集团同比增速更快（252.5% vs 5.9%），亚朵集团自由现金流更多（$210.7M vs $161.8M）
亚朵生活控股是中国领先的文旅生活服务企业，主营中高端连锁酒店运营业务，面向商旅及休闲出行人群提供高品质住宿服务，同时配套布局生活文创零售、场景体验等多元业务，覆盖国内核心城市及部分海外市场。
Revvity是一家美国生命科学与诊断领域企业，主要服务制药、生物技术行业客户，重点围绕细胞治疗、基因治疗等前沿技术领域提供相关产品与解决方案，其前身为业务布局多元的老牌企业珀金埃尔默。
ATAT vs RVTY — 直观对比
营收规模更大
ATAT
是对方的1.0倍
$772.1M
营收增速更快
ATAT
高出246.7%
5.9%
净利率更高
ATAT
高出4.9%
12.7%
自由现金流更多
ATAT
多$48.9M
$161.8M
损益表 — Q3 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $789.6M | $772.1M |
| 净利润 | $139.1M | $98.4M |
| 毛利率 | — | — |
| 营业利润率 | 22.5% | 14.5% |
| 净利率 | 17.6% | 12.7% |
| 营收同比 | 252.5% | 5.9% |
| 净利润同比 | 322.2% | 3.9% |
| 每股收益（稀释后） | $0.33 | $0.86 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ATATRVTY
| Q4 25 | — | $772.1M | ||
| Q3 25 | $789.6M | $698.9M | ||
| Q2 25 | — | $720.3M | ||
| Q1 25 | — | $664.8M | ||
| Q4 24 | — | $729.4M | ||
| Q3 24 | $224.0M | $684.0M | ||
| Q2 24 | — | $691.7M | ||
| Q1 24 | $203.4M | $649.9M |
净利润ATATRVTY
| Q4 25 | — | $98.4M | ||
| Q3 25 | $139.1M | $46.7M | ||
| Q2 25 | — | $53.9M | ||
| Q1 25 | — | $42.2M | ||
| Q4 24 | — | $94.6M | ||
| Q3 24 | $33.0M | $94.4M | ||
| Q2 24 | — | $55.4M | ||
| Q1 24 | $35.6M | $26.0M |
毛利率ATATRVTY
| Q4 25 | — | — | ||
| Q3 25 | — | 53.6% | ||
| Q2 25 | — | 54.5% | ||
| Q1 25 | — | 56.5% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 56.3% | ||
| Q2 24 | — | 55.7% | ||
| Q1 24 | — | 54.6% |
营业利润率ATATRVTY
| Q4 25 | — | 14.5% | ||
| Q3 25 | 22.5% | 11.7% | ||
| Q2 25 | — | 12.6% | ||
| Q1 25 | — | 10.9% | ||
| Q4 24 | — | 16.3% | ||
| Q3 24 | 14.7% | 14.3% | ||
| Q2 24 | — | 12.4% | ||
| Q1 24 | 22.1% | 6.8% |
净利率ATATRVTY
| Q4 25 | — | 12.7% | ||
| Q3 25 | 17.6% | 6.7% | ||
| Q2 25 | — | 7.5% | ||
| Q1 25 | — | 6.4% | ||
| Q4 24 | — | 13.0% | ||
| Q3 24 | 14.7% | 13.8% | ||
| Q2 24 | — | 8.0% | ||
| Q1 24 | 17.5% | 4.0% |
每股收益（稀释后）ATATRVTY
| Q4 25 | — | $0.86 | ||
| Q3 25 | $0.33 | $0.40 | ||
| Q2 25 | — | $0.46 | ||
| Q1 25 | — | $0.35 | ||
| Q4 24 | — | $0.77 | ||
| Q3 24 | $0.08 | $0.77 | ||
| Q2 24 | — | $0.45 | ||
| Q1 24 | $0.09 | $0.21 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $669.2M | $919.9M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $405.0M | $7.3B |
| 总资产 | $1.1B | $12.2B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资ATATRVTY
| Q4 25 | — | $919.9M | ||
| Q3 25 | $669.2M | $931.4M | ||
| Q2 25 | — | $991.8M | ||
| Q1 25 | — | $1.1B | ||
| Q4 24 | — | $1.2B | ||
| Q3 24 | $506.0M | $1.2B | ||
| Q2 24 | — | $2.0B | ||
| Q1 24 | $520.7M | $1.7B |
总债务ATATRVTY
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | $277.0K | — |
股东权益ATATRVTY
| Q4 25 | — | $7.3B | ||
| Q3 25 | $405.0M | $7.4B | ||
| Q2 25 | — | $7.6B | ||
| Q1 25 | — | $7.6B | ||
| Q4 24 | — | $7.7B | ||
| Q3 24 | $291.3M | $7.9B | ||
| Q2 24 | — | $7.9B | ||
| Q1 24 | $323.5M | $7.8B |
总资产ATATRVTY
| Q4 25 | — | $12.2B | ||
| Q3 25 | $1.1B | $12.1B | ||
| Q2 25 | — | $12.4B | ||
| Q1 25 | — | $12.4B | ||
| Q4 24 | — | $12.4B | ||
| Q3 24 | $927.8M | $12.8B | ||
| Q2 24 | — | $13.4B | ||
| Q1 24 | $936.3M | $13.4B |
负债/权益比ATATRVTY
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 0.00× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $216.6M | $182.0M |
| 自由现金流经营现金流 - 资本支出 | $210.7M | $161.8M |
| 自由现金流率自由现金流/营收 | 26.7% | 21.0% |
| 资本支出强度资本支出/营收 | 0.8% | 2.6% |
| 现金转化率经营现金流/净利润 | 1.56× | 1.85× |
| 过去12个月自由现金流最近4个季度 | $359.6M | $509.4M |
8季度趋势，按日历期对齐
经营现金流ATATRVTY
| Q4 25 | — | $182.0M | ||
| Q3 25 | $216.6M | $138.5M | ||
| Q2 25 | — | $134.3M | ||
| Q1 25 | — | $128.2M | ||
| Q4 24 | — | $174.2M | ||
| Q3 24 | $84.8M | $147.9M | ||
| Q2 24 | — | $158.6M | ||
| Q1 24 | $19.8M | $147.6M |
自由现金流ATATRVTY
| Q4 25 | — | $161.8M | ||
| Q3 25 | $210.7M | $120.0M | ||
| Q2 25 | — | $115.5M | ||
| Q1 25 | — | $112.2M | ||
| Q4 24 | — | $149.8M | ||
| Q3 24 | $83.3M | $125.6M | ||
| Q2 24 | — | $136.6M | ||
| Q1 24 | $18.1M | $129.7M |
自由现金流率ATATRVTY
| Q4 25 | — | 21.0% | ||
| Q3 25 | 26.7% | 17.2% | ||
| Q2 25 | — | 16.0% | ||
| Q1 25 | — | 16.9% | ||
| Q4 24 | — | 20.5% | ||
| Q3 24 | 37.2% | 18.4% | ||
| Q2 24 | — | 19.7% | ||
| Q1 24 | 8.9% | 20.0% |
资本支出强度ATATRVTY
| Q4 25 | — | 2.6% | ||
| Q3 25 | 0.8% | 2.6% | ||
| Q2 25 | — | 2.6% | ||
| Q1 25 | — | 2.4% | ||
| Q4 24 | — | 3.4% | ||
| Q3 24 | 0.7% | 3.3% | ||
| Q2 24 | — | 3.2% | ||
| Q1 24 | 0.9% | 2.7% |
现金转化率ATATRVTY
| Q4 25 | — | 1.85× | ||
| Q3 25 | 1.56× | 2.97× | ||
| Q2 25 | — | 2.49× | ||
| Q1 25 | — | 3.03× | ||
| Q4 24 | — | 1.84× | ||
| Q3 24 | 2.57× | 1.57× | ||
| Q2 24 | — | 2.87× | ||
| Q1 24 | 0.56× | 5.67× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ATAT
暂无分部数据
RVTY
| Immunodiagnostics | $240.8M | 31% |
| Life Sciences | $191.4M | 25% |
| Reproductive Health | $149.3M | 19% |
| Segment Operating Income | $132.0M | 17% |
| Software | $62.3M | 8% |
